UroGen Pharma Ltd. - Ordinary Shares — 貸借対照表 (NASDAQ:URGN) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 122 M119.75 M135.62 M178.31 M285.71 M200.46 M 負債合計 25.65 M111.33 M224.98 M243.52 M294.51 M305.93 M 純資産合計 96.36 M8.41 M-89.36 M-65.21 M-8.8 M-105.47 M 負債および純資産合計 122 M119.75 M135.62 M178.31 M285.71 M200.46 M 有利子負債合計 ——97.54 M98.55 M121.73 M123.48 M 純負債 ——97.54 M-42.95 M-119.97 M1.71 M

ニュース

IBRX and the BCG Shortage: Deals That Could Expand Demand

UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript

Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

IBRX: What Anktiva's Bladder Data Says About 2026 Sales

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers

UroGen PharmaがTD Cowenカンファレンスで戦略的成長と革新を提示

UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation

Oppenheimer、Zusduri売上を評価しUroGen Pharmaの目標株価を34ドルに引き上げ

Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales

Oppenheimer、Zusduri好調な売上を受けUroGen Pharma株の投資判断を維持